Illumina confirms failed bid for Complete Genomics Illumina (ILMN) confirmed in a regulatory filing that it is “Party H” as named in the Schedule 14D-9 filed by Complete Genomics (GNOM) in connection with the tender offer by Beta Acquisition Corporation, a wholly owned subsidiary of BGI-Shenzhen, to purchase all of the outstanding common stock of Complete Genomics. Illumina further confirmed that it submitted proposals to acquire Complete Genomics. Illumina’s most recent proposal, submitted on November 5, included the following terms: a per share cash purchase price of $3.30, which represented approximately a 5% premium over the consideration offered by BGI; financed with cash-on-hand; and without any condition for further due diligence. Complete Genomics called Illumina's offer inadequate.
News For ILMN;GNOM From The Last 14 Days
Check below for free stories on ILMN;GNOM the last two weeks.
Subscribe for More Information